JNJ-95475939, Placebo JNJ-95475939, Dupixent 300 mg solution for injection in pre-filled syringe
95475939ADM2001
Phase 2 small_molecule active
Quick answer
JNJ-95475939, Placebo JNJ-95475939, Dupixent 300 mg solution for injection in pre-filled syringe for Moderate to Severe Atopic Dermatitis is a Phase 2 program (small_molecule) at Janssen-Cilag International N.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Janssen-Cilag International N.V.
- Indication
- Moderate to Severe Atopic Dermatitis
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active